Medicine & Life Sciences
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
18%
Acute Myeloid Leukemia
36%
Agammaglobulinaemia Tyrosine Kinase
6%
alvocidib
9%
Anemia
11%
Azacitidine
17%
B-Cell Chronic Lymphocytic Leukemia
33%
B-Cell Lymphoma
8%
B-Lymphocytes
5%
Bone Marrow
6%
Bortezomib
10%
Clinical Trials
5%
Cytarabine
7%
Dasatinib
6%
Decitabine
8%
Drug Therapy
10%
Essential Thrombocythemia
19%
GATA2 Deficiency
5%
Hematologic Neoplasms
6%
Histone Deacetylase Inhibitors
7%
Idarubicin
5%
INCB018424
72%
isavuconazole
5%
ivosidenib
7%
Janus Kinase 2
8%
Janus Kinase Inhibitors
22%
Leukemia
6%
Leukemia, Myeloid, Chronic Phase
6%
Leukemia, Myelomonocytic, Chronic
7%
Mutation
14%
Myelodysplastic Syndromes
12%
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
9%
Neoplasms
21%
PCI 32765
17%
Platelet Count
5%
Polycythemia Vera
24%
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5%
Primary Myelofibrosis
100%
rasburicase
5%
Safety
9%
Sorafenib
10%
Survival
20%
Systemic Mastocytosis
16%
Therapeutics
21%
Thrombocytopenia
10%
Thrombocytosis
9%
Tumor Lysis Syndrome
5%
venetoclax
48%
Vorinostat
7%